Jacques Himber

USPTO Granted Patents = 14 (Patent Applications = 1)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 4)

Average Co-Inventor Count = 8.6

ph-index = 6

Forward Citations = 152(Granted Patents)

Company Filing History:

12 out of 4,942

Hoffmann-la Roche Inc.

Laboratories Alcon S.a.

patent

Years Active: 1988-2013

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. RE44389 - Methods of inhibiting the binding of P-selectin to PSGL-1 with anti-P-selectin antibodies (2013-07-22),

2. RE44359 - Nucleic acid molecules encoding anti-P-selectin antibodies (2013-07-08),

3. RE43568 - Anti-P-selectin antibodies (2012-08-06),

4. 7824684 - Methods of inhibiting the binding of P-selectin to PSGL-1 with anti-P-selectin antibodies (2010-11-02),

5. 7754867 - Nucleic acid molecules encoding anti-P-selectin antibodies (2010-07-13),

6. 7601752 - Pyrrolidine derivatives (2009-10-13),

7. 7563441 - Anti-P-selectin antibodies (2009-07-21),

8. 7550487 - Pyrrolidine-3,4-dicarboxamide derivatives (2009-06-23),

9. 7501413 - Dicarboxamide derivatives (2009-03-10),

10. 6441177 - Tertiary amines (2002-08-27),

11. 6034275 - Tertiary amines (2000-03-07),

12. 5856503 - Aminoalkyl-substituted benzo-heterocyclic compounds (1999-01-05),

13. 4897412 - Imidazolines useful in lowering intraocular pressure (1990-01-30),

14. 4766151 - Ethers and oxime ethers of alkylamino alcohols as medicaments and novel (1988-08-23),

Title: Trailblazer Inventor Jacques Himber: Pioneering Innovation in Guebwiller, France

Introduction:

Jacques Himber, a visionary inventor based in Guebwiller, France, is renowned for his strong passion for innovation and his unwavering dedication to creating a better world through technology. His inventive spirit and commitment to excellence have established him as a true pioneer in the field, inspiring others to push the boundaries of what is possible.

Latest Patents:

Jacques Himber holds an impressive total of 14 patents, showcasing his innovative prowess. Two of his latest patents include groundbreaking methods for inhibiting the binding of P-selectin to PSGL-1 with anti-P-selectin antibodies. These antibodies, with unique properties and derived from human origin, provide significant benefits for patients suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).

Career Highlights:

Throughout his illustrious career, Jacques Himber has made significant contributions to the field of biotechnology. His work at renowned companies such as Hoffmann-La Roche Inc. and Laboratoires Pos has been instrumental in driving forward groundbreaking innovations. His innovative approach and relentless pursuit of excellence have set him apart as a trailblazer in the industry.

Collaborations:

Jacques Himber has had the privilege of collaborating with esteemed professionals in the field, including his coworkers Yvo Graus and Miranda Jansen-Molenaar. These collaborations have not only enriched his own work but have also led to the development of groundbreaking technologies that have made a profound impact on the industry.

Conclusion:

In conclusion, Jacques Himber stands as a shining example of a true innovator whose dedication to driving positive change through technology is unparalleled. His pioneering spirit, coupled with his passion for innovation, continues to inspire and motivate others to strive for excellence in their own endeavors. Through his remarkable inventions and unwavering commitment to creating a better world, Jacques Himber has cemented his legacy as a visionary inventor shaping the future of biotechnology.

This text is generated by artificial intelligence and may not be accurate.